X4 Pharmaceuticals (XFOR) Cost of Revenue (2024 - 2025)
X4 Pharmaceuticals posted quarterly Cost of Revenue of $364000.0 for Q4 2025, up 20.53% year-on-year from $302000.0 in Q4 2024, and up 3.7% on a QoQ basis from $351000.0 in Q3 2025.
X4 Pharmaceuticals (XFOR) has 2 years of Cost of Revenue data on file, last reported at $364000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cost of Revenue rose 20.53% year-over-year to $364000.0; the trailing twelve-month figure through Dec 2025 stood at $5.8 million (up 622.33% YoY), and the FY2025 full-year result was $5.8 million, up 622.33% from the prior year.
- Cost of Revenue for Q4 2025 stood at $364000.0, up from $351000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $4.7 million in Q1 2025 and bottomed at $227000.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 207.52 Mn |
| 10 | X4 Pharmaceuticals | 182.28 Mn | 182.28 Mn | 2.20 Mn | 364,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 364,000.00 |
| Dec 31, 2025 | 364,000.00 |
| Sep 30, 2025 | 351,000.00 |
| Sep 30, 2025 | 351,000.00 |
| Jun 30, 2025 | 326,000.00 |
| Jun 30, 2025 | 326,000.00 |
| Mar 31, 2025 | 4.72 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Dec 31, 2024 | 302,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Jun 30, 2024 | 268,000.00 |
| Jun 30, 2024 | 268,000.00 |